Company news

Amplia Therapeutics Ltd. news in 2024

Amplia Therapeutics Ltd.'s news releases, calls and decks from 2024, newest first.

View company

Security Class Reinstatement to Quotation - ATXOA

December 23, 2024

App 4D and Financial Report Half Year ended 30 Sep 2024

November 27, 2024

Security Class Suspension from Quotation

November 24, 2024

Amplia Successfully Completes Institutional Offer

October 31, 2024

Capital Raise Presentation

October 30, 2024

Amplia to Raise up to $13m for ACCENT and US Trials

October 30, 2024

Interim Data From Accent Pancreatic Cancer Trial

October 30, 2024

Sixth Confirmed Response in Pancreatic Cancer Trial

September 22, 2024

FDA Fast Track Designation for Narmafotinib

September 19, 2024

Fifth Confirmed Response in ACCENT Trial

August 20, 2024

Amplia Receives R&D Tax Rebate Totalling $3.2 Million

August 11, 2024

Granting of Key Patent in Europe and Japan

August 7, 2024

Additional Patient Response in Pancreatic Cancer Trial

August 5, 2024

Sustained Reduction in Tumour Size Seen In Pancreatic Trial

July 25, 2024

First 26 Patients recruited in Phase 2A ACCENT Trial

July 3, 2024

Preliminary Final Report and Annual Report YE 31 March 2024

May 30, 2024

$4.27m Offer Successfully Completed and ACCENT Trial Update

May 14, 2024

Rights Issue Investor Slide Deck

April 16, 2024

Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27

April 16, 2024

Update on ACCENT Trial in Pancreatic Cancer

March 26, 2024

FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US

January 17, 2024

Amplia Reports First Patient Dosing In Phase 2a Accent Trial

January 16, 2024

Decks in 2024